A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma
Status:
Recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
This is a randomized, open, multicenter phase II/III trial to compare the efficacy and safety
of QL1706 and carrilizumab combined with gemcitabine and cisplatin in first-line treatment of
recurrent or metastatic nasopharyngeal carcinoma.